Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

OncoImmunology

Volumn 1, Issue 4, 2012, Pages 477-486

  Cheung, Nai Kong V ^a   Guo, Hongfen ^a   Hu, Jian ^a   Tassev, Dimiter V ^a   Cheung, Irene Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity (ADCC); Chimeric; Complement mediated cytotoxicity (CMC); Humanized; Monoclonal antibodies (MoAb); Peripheral blood mononuclear cells (PBMC); Polymorphonuclear leukocytes (PMN)

Indexed keywords

ANTINEOPLASTIC AGENT; CD16 ANTIGEN; CD32 ANTIGEN; GLOBULIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY 3F8 IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY M3F8; MONOCLONAL ANTIBODY M3F8 IMMUNOGLOBULIN G1; PROTEIN A; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMPARATIVE EFFECTIVENESS; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG PURIFICATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN TARGETING; SURFACE PLASMON RESONANCE;

EID: 84877799310     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19864     Document Type: Article

References (49)

1. Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008;8:1151-1158. PMID:18613766; http://dx.doi.org/10.1517/14712598.8.8.1151
2. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008;14:178-183. PMID:18536557; http://dx.doi.org/10.1097/PPO.0b013e318172d71a
3. Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001;19:2821-2828. PMID:11387353
4. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-2491. PMID:12829667; http://dx.doi.org/10.1200/JCO.2003.09.122
5. Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma .1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008;44:1552-1558. PMID:18424129; http://dx.doi.org/10.1016/j.ejca.2008.03.013
6. Azarova AM, Gautam G, George RE. Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 2011;21:267-275. PMID:21945349; http://dx.doi.org/10.1016/j.semcancer.2011.09.005
7. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, European Neuroblastoma Study Group & Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008;9:247-256. PMID:18308250; http://dx.doi.org/10.1016/S1470-2045(08)70069-X
8. Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. Decay-accelerating factor protects human tumor cells from complementmediated cytotoxicity in vitro. J Clin Invest 1988;81:1122-1128. PMID:2450893; http://dx.doi.org/10.1172/JCI113426
9. Chen S, Caragine T, Cheung NK, Tomlinson S. CD59 expressed on a tumor cell surface modulates decayaccelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res 2000;60:3013-3018. PMID:10850450
10. Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 1992;79:1484-1490. PMID:1347707
11. Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002;99:4166-4173. PMID:12010822; http://dx.doi.org/10.1182/blood.V99.11.4166
12. Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000;18:10-18. PMID:10661568; http://dx.doi.org/10.1634/stemcells.18-1-10
13. Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, Bare CV, et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 2000;96:754-762. PMID:10887145
14. Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer 2007;48:430-434. PMID:16421906; http://dx.doi.org/10.1002/pbc.20765
15. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985; 45:2642-9; PMID:2580625
16. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989;49:2857-2861. PMID:2720646
17. Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 1989;125:191-202. PMID:2514231; http://dx.doi.org/10.1016/0022-1759(89)90093-8
18. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric antiganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51:144-149. PMID:1988079
19. Barker E, Reisfeld RA. A mechanism for neutrophilmediated lysis of human neuroblastoma cells. Cancer Res 1993;53:362-367. PMID:8417829
20. Mueller BM, Reisfeld RA, Gillies SD. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci U S A 1990;87:5702-5705. PMID:2198570; http://dx.doi.org/10.1073/pnas.87.15.5702
21. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990;144:1382-1386. PMID:2303711
22. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004;22:3549-3557. PMID: 15337804; http://dx.doi.org/10.1200/JCO.2004.08.143
23. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009;27:85-91. PMID:19047298; http://dx.doi.org/10.1200/JCO.2006.10.3564
24. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al & Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-1334. PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
25. Kushner B, Kramer K, Modak S, Cheung NK. Anti-GD2 anitbody 3F8 plus granulocyte-macrophage colony stimulating factor (GM-CSF) for primary refractory neuroblastoma (NB) in the bone marrow (BM). Proc Am Soc Clin Oncol 2007;25:526s.
26. Cheung NK, Kushner BH, Kramer K, Modak S, Wolden S, LaQuaglia M. Anti-GD2 Murine Monoclonal Antibody (MoAb) 3F8 for Consolidation of First Complete/Very Good Partial Remission of High Risk Stage 4 Neuroblastoma (NB). Advances in Neuroblastoma Research (ANR). Stockholm, Sweden, 2010.
27. Patel K, Rossell RJ, Pemberton LF, Cheung NKV, Walsh FS, Moore SE, et al. Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2. Br J Cancer 1989;60:861-866. PMID:2481486; http://dx.doi.org/10.1038/bjc.1989.380
28. Bergman I, Basse PH, Barmada MA, Griffin JA, Cheung NK. Comparison of in vitro antibodytargeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother 2000;49:259-266. PMID:10941909; http://dx.doi.org/10.1007/s002620000120
29. Yu A, Gilman AL, Ozkaynak MF, London WB, Kreissman S, Chen HX, et al. A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032. J Clin Oncol 2009;27:85-91. PMID:19047298
30. Kushner BH, Kramer K, Cheung NKV. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189-4194. PMID:11709561
31. Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-2180. PMID:9626218
32. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colonystimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000;18:4077-4085. PMID:11118469
33. Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, et al. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res 2009;15:5923-5930. PMID:19737959; http://dx.doi.org/10.1158/1078-0432.CCR-08-2963
34. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-3947. PMID: 12975461; http://dx.doi.org/10.1200/JCO.2003.05.013
35. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004;10:6248-6255. PMID:15448014; http://dx.doi.org/10.1158/1078-0432.CCR-04-0850
36. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer. J Clin Oncol 2008;26:1789-1796. PMID:18347005; http://dx.doi.org/10.1200/JCO.2007.14.8957
37. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-1129. PMID:19164213; http://dx.doi.org/10.1200/JCO.2008.18.0463
38. Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006;24:2885-2890. PMID:16682723; http://dx.doi.org/10.1200/JCO.2005.04.6011
39. Hettmer S, McCarter R, Ladisch S, Kaucic K. Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer 2004;91:389-397. PMID:15187999
40. Hettmer S, Malott C, Woods W, Ladisch S, Kaucic K. Biological stratification of human neuroblastoma by complex "B" pathway ganglioside expression. Cancer Res 2003;63:7270-7276. PMID:14612523
41. Gong Y, Tagawa Y, Lunn MP, Laroy W, Heffer-Lauc M, Li CY, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002;125:2491-2506. PMID:12390975; http://dx.doi.org/10.1093/brain/awf258
42. Saarinen UM, Coccia PF, Gerson S, Pelley R, Donovan D, Cheung NKV. In vitro eradication of neuroblastoma (NB) cells by monoclonal antibody (Mab) and human complement (C'): a method for purging autologous bone marrow (BM). Proc Am Assoc Cancer Res 1985;26:291.
43. Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, et al. Depletion of the C3 component of complement enhances the ability of rituximabcoated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009;114:5322-5330. PMID: 19805620; http://dx.doi.org/10.1182/blood-2009-01-200469
44. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008;14:6697-6703. PMID:18927313;http://dx.doi.org/10.1158/1078-0432.CCR-08-0745
45. Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 2010;10:200-209. PMID:20201786; http://dx.doi.org/10.2174/156800910791054167
46. Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med 2004;45:867-877. PMID:15136638
47. Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 2001;61:4048-4054. PMID: 11358824
48. Catimel B, Scott AM, Lee FT, Hanai N, Ritter G, Welt S, et al. Direct immobilization of gangliosides onto goldcarboxymethyldextran sensor surfaces by hydrophobic interaction: applications to antibody characterization. Glycobiology 1998;8:927-938. PMID:9675226; http://dx.doi.org/10.1093/glycob/8.9.927
49. Hu J, Huang X, Ling CC, Bundle DR, Cheung NK. Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody. J Immunol 2009;183:5748-5755. PMID:19812201; http://dx.doi.org/10.4049/jimmunol.0901409